Issue 5/2012
Content (16 Articles)
Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?
Hannah R. Wardill, Joanne M. Bowen, Rachel J. Gibson
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy
Y. Z. Chen, J. Y. Xue, C. M. Chen, B. L. Yang, Q. H. Xu, F. Wu, F. Liu, X. Ye, X. Meng, G. Y. Liu, Z. Z. Shen, Z. M. Shao, J. Wu
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer
Minoru Fukuda, Yoichi Nakamura, Akitoshi Kinoshita, Yoshifumi Soejima, Hiroyuki Yamaguchi, Takaya Ikeda, Koichi Izumikawa, Hiroshi Takatani, Masaaki Fukuda, Hiroshi Soda, Nobuyuki Hayashi, Kazuhiro Tsukamoto, Mikio Oka, Shigeru Kohno
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors
Anne-Charlotte Dubbelman, Alana Upthagrove, Jos H. Beijnen, Serena Marchetti, Eugene Tan, Kimberly Krone, Suraj Anand, Jan H. M. Schellens
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02
Yoon Hee Choi, Sang Cheul Oh, Jun Suk Kim, Seung-Hyun Nam, Bong-Seog Kim, Sang-Hee Cho, Ik Joo Chung, Eun-Kee Song, Chang-Yeol Yim, Jin Ho Baek, Hei-Cheul Jeung, Young Seon Hong, Sung Hyun Yang, Hye Jin Kang
A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
R. Salazar, R. J. Jones, A. Oaknin, D. Crawford, C. Cuadra, C. Hopkins, M. Gil, C. Coronado, A. Soto-Matos, M. Cullell-Young, J. L. Iglesias Dios, T. R. J. Evans
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer
Hyun-Jeong Shim, Dae-Eun Kim, Jun-Eul Hwang, Woo-Kyun Bae, Taek-Keun Nam, Kook-Joo Na, Sang-Hee Cho, Ik-Joo Chung
Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer
Hiroki Goya, Hiroshi Kuraishi, Shigeru Koyama, Takashi Ichiyama, Fumiaki Yoshiike, Kazuya Hirai, Toshihiko Agatsuma, Kazunari Tateishi, Shintaro Kanda, Hiroshi Yamamoto, Keishi Kubo, Tomonobu Koizumi
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
Jeffrey R. Infante, Vicki L. Keedy, Suzanne F. Jones, William C. Zamboni, Emily Chan, Johanna C. Bendell, Wooin Lee, Huali Wu, Satoshi Ikeda, Hiroshi Kodaira, Mace L. Rothenberg, Howard A. Burris III
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors
Song Dong, Xu-Chao Zhang, Hua Cheng, Jian-Quan Zhu, Zhi-Hong Chen, Yi-Fang Zhang, Zhi Xie, Yi-Long Wu
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
N. Chen, C. Kasserra, J. Reyes, L. Liu, H. Lau
Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer
Colm Farrell, Charles Schweizer, Jason Wustner, Susan Weil, Masayuki Namiki, Tomohisa Nakano, Kenya Nakai, Martin D. Phillips
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy
Byung Woog Kang, Ji Yun Jeong, Yee Soo Chae, Soo Jung Lee, Yoo Jin Lee, Jun Young Choi, In-Kyu Lee, Seong Woo Jeon, Han Ik Bae, Da Keun Lee, Oh-kyoung Kwon, Ho Young Chung, Wansik Yu, Jong Gwang Kim
A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma
Zarah Glad Zimling, Jens Benn Sørensen, Thomas Alexander Gerds, Cecilia Bech, Claus Bøgelund Andersen, Eric Santoni-Rugiu
Phase I trial of pomalidomide given for patients with advanced solid tumors
Matthew M. Cooney, Charles Nock, Joseph Bokar, Smitha Krishnamurthi, Joseph Gibbons, Mary Beth Rodal, Anne Ness, Scot C. Remick, Robert Dreicer, Afshin Dowlati
Erratum to: The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response
Trevor G. Glaros, Luke H. Stockwin, Michael E. Mullendore, Brian Smith, Bethanie L. Morrison, Dianne L. Newton